Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.05.2023 | Case report

Bortezomib/cytotoxic-t-lymphocytes/daratumumab

Lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Pavasovic V, et al. FULMINANT, EBV DRIVEN PLASMACYTIC POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) WITH LOSS OF 1P AND GAIN OF TP53/CEP17 AND IGH BONE MARROW INVOLVEMENT AFTER LIVER TRANSPLANT IN 17-MONTH OLD BOY. Leukemia Research 121 (Suppl.): S53-S54 (plus poster) abstr. 085, Oct 2022. Available from: URL: http://doi.org/10.1016/S0145-2126%2822%2900279-X [abstract] Pavasovic V, et al. FULMINANT, EBV DRIVEN PLASMACYTIC POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) WITH LOSS OF 1P AND GAIN OF TP53/CEP17 AND IGH BONE MARROW INVOLVEMENT AFTER LIVER TRANSPLANT IN 17-MONTH OLD BOY. Leukemia Research 121 (Suppl.): S53-S54 (plus poster) abstr. 085, Oct 2022. Available from: URL: http://​doi.​org/​10.​1016/​S0145-2126%2822%2900279-X [abstract]
Metadaten
Titel
Bortezomib/cytotoxic-t-lymphocytes/daratumumab
Lack of efficacy: case report
Publikationsdatum
01.05.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-38721-z

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Tozinameran

Case report

Amlodipine